Results 21 to 30 of about 1,734 (194)

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues [PDF]

Molecules, 2020
The strong inhibition of Human Cytomegalovirus (HCMV) replication by benzimidazole nucleosides, like Triciribine and Maribavir, has prompted us to expand the structure–activity relationships of the benzimidazole series, using as a central core the ...
Georgios Papadakis, Maria Gerasi, Robert Snoeck, Panagiotis Marakos, Graciela Andrei, Nikolaos Lougiakis, Nicole Pouli   +6 more
doaj   +4 more sources

Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

New England Journal of Medicine, 2019
Maribavir is a benzimidazole riboside with activity against cytomegalovirus (CMV). The safety and efficacy of maribavir for preemptive treatment of CMV infection in transplant recipients is not known.In a phase 2, open-label, maribavir dose-blinded trial, recipients of hematopoietic-cell or solid-organ transplants (≥18 years of age, with CMV ...
Johan A Maertens, Xavier Poiré, Marc Uknis   +2 more
exaly   +3 more sources

In Silico Analysis of Mechanisms of Maribavir-Induced Inhibition and Drug Resistance Mutations in pUL97 Kinase Structural Prediction with AlphaFold2 [PDF]

Viruses
Infections with cytomegalovirus (CMV) can result in increased morbidity and mortality in immunocompromised patients. The pUL97 kinase is a critical enzyme in the regulation of CMV replication.
Jocelyne Piret, Guy Boivin
doaj   +2 more sources

Revisiting cytomegalovirus in pediatric allogeneic hematopoietic stem cell transplant recipients: current strategies for prevention and management in the letermovir era [PDF]

Frontiers in Pediatrics
CMV infection remains the most common clinically significant infection in pediatric allogeneic hematopoietic stem cell (HCT) recipients, with seropositive recipients of transplants from seronegative donors at the highest risk for complications. In recent
Lisa Hiskey, Diego R. Hijano, Diego R. Hijano, Ramia Zakhour   +3 more
doaj   +2 more sources

Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023 [PDF]

Transplant International
Cytomegalovirus (CMV) infection poses significant challenges in solid organ transplant (SOT) recipients, impacting graft outcomes, morbidity, and in some cases survival.
Luca Toti, Nassim Kamar, Sophie Alain, Sophie Alain, Oriol Manuel, Nikolina Basic-Jukic, Paolo Antonio Grossi, Hannah Kaminski, Paolo Solidoro, Luciano Potena   +9 more
doaj   +2 more sources

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT. [PDF]

Rev Med Virol
ABSTRACT Human cytomegalovirus (HCMV) reactivation is a common and significant complication after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), causing potentially life‐threatening disease. Antiviral therapy approaches for HCMV are often limited by toxicities and the risk of developing antiviral drug resistance.
Sutrave G, Yong MK, Kaplan D, Gottlieb DJ, Abendroth A, Slobedman B, Blyth E, Stern L.   +7 more
europepmc   +2 more sources

Cytomegalovirus and Crohn’s disease as competing causes of small bowel inflammation after double-lung transplantation [PDF]

European Clinical Respiratory Journal
Background Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract.
Julie Hansen Niklassen, Christian Lodberg Hvas, Kristian Schønning, Kasper Sommerlund Moestrup, Marie Helleberg, Michael Perch, Elisabeth Bendstrup   +6 more
doaj   +2 more sources

Maribavir

American Journal of Health-System Pharmacy, 2022
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Terri L. Levien, Danial E. Baker
openaire   +4 more sources

A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient [PDF]

Transplant International
Helen Pearce, Emma K. Montgomery, Neil Sheerin, Neil Sheerin, Helena Ellam   +4 more
doaj   +3 more sources

Real-World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual-Center Cohort. [PDF]

Pharmacotherapy
ABSTRACT Background Cytomegalovirus (CMV) is a major opportunistic infection in solid organ transplant (SOT) recipients. Although valganciclovir is first‐line for CMV treatment, its use may be limited by resistance and myelotoxicity. Letermovir (LET) and maribavir (MBV) are increasingly used as alternative therapies, though real‐world outcomes remain ...
Xu MT, Wright A, Mah A, Matic N, Lowe C, Hong C, Belga S, Tsai WP.   +7 more
europepmc   +2 more sources